Daina Graybosch
Stock Analyst at Leerink Partners
(0.83)
# 3,588
Out of 4,818 analysts
119
Total ratings
34.09%
Success rate
-14.21%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Daina Graybosch
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TSVT 2seventy bio | Downgrades: Market Perform | $9 → $5 | $4.99 | +0.30% | 6 | Mar 11, 2025 | |
| MRK Merck & Co. | Maintains: Outperform | $136 → $119 | $79.81 | +49.10% | 19 | Jan 13, 2025 | |
| LVTX LAVA Therapeutics | Downgrades: Market Perform | $11 → $2 | $1.39 | +43.88% | 6 | Dec 12, 2024 | |
| BOLT Bolt Biotherapeutics | Downgrades: Market Perform | $3 → $1 | $0.39 | +157.07% | 8 | May 15, 2024 | |
| ACLX Arcellx | Maintains: Outperform | $35 → $39 | $63.97 | -39.03% | 5 | Mar 30, 2023 | |
| NKTR Nektar Therapeutics | Maintains: Market Perform | $5 → $3 | $0.73 | +309.44% | 10 | Feb 24, 2023 | |
| IPSC Century Therapeutics | Maintains: Outperform | $20 → $14 | $0.53 | +2,540.02% | 4 | Jan 6, 2023 | |
| FATE Fate Therapeutics | Maintains: Outperform | $62 → $10 | $1.35 | +640.74% | 7 | Jan 6, 2023 | |
| AFMD Affimed | Maintains: Outperform | $100 → $60 | $0.90 | +6,566.67% | 7 | Dec 12, 2022 | |
| IPHA Innate Pharma | Maintains: Outperform | $10 → $9 | $1.99 | +352.26% | 10 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $38 | $8.41 | +351.84% | 2 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $30 → $8 | $4.08 | +96.08% | 4 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $223 → $224 | $120.43 | +86.01% | 16 | Jul 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $2.19 | +1,269.86% | 1 | Jul 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $60 → $59 | $7.36 | +701.63% | 7 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $17 | $0.89 | +1,802.63% | 3 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $9 | $1.48 | +508.11% | 4 | Feb 25, 2022 |
2seventy bio
Mar 11, 2025
Downgrades: Market Perform
Price Target: $9 → $5
Current: $4.99
Upside: +0.30%
Merck & Co.
Jan 13, 2025
Maintains: Outperform
Price Target: $136 → $119
Current: $79.81
Upside: +49.10%
LAVA Therapeutics
Dec 12, 2024
Downgrades: Market Perform
Price Target: $11 → $2
Current: $1.39
Upside: +43.88%
Bolt Biotherapeutics
May 15, 2024
Downgrades: Market Perform
Price Target: $3 → $1
Current: $0.39
Upside: +157.07%
Arcellx
Mar 30, 2023
Maintains: Outperform
Price Target: $35 → $39
Current: $63.97
Upside: -39.03%
Nektar Therapeutics
Feb 24, 2023
Maintains: Market Perform
Price Target: $5 → $3
Current: $0.73
Upside: +309.44%
Century Therapeutics
Jan 6, 2023
Maintains: Outperform
Price Target: $20 → $14
Current: $0.53
Upside: +2,540.02%
Fate Therapeutics
Jan 6, 2023
Maintains: Outperform
Price Target: $62 → $10
Current: $1.35
Upside: +640.74%
Affimed
Dec 12, 2022
Maintains: Outperform
Price Target: $100 → $60
Current: $0.90
Upside: +6,566.67%
Innate Pharma
Nov 15, 2022
Maintains: Outperform
Price Target: $10 → $9
Current: $1.99
Upside: +352.26%
Nov 3, 2022
Maintains: Outperform
Price Target: $40 → $38
Current: $8.41
Upside: +351.84%
Aug 29, 2022
Downgrades: Market Perform
Price Target: $30 → $8
Current: $4.08
Upside: +96.08%
Jul 29, 2022
Maintains: Outperform
Price Target: $223 → $224
Current: $120.43
Upside: +86.01%
Jul 18, 2022
Initiates: Outperform
Price Target: $30
Current: $2.19
Upside: +1,269.86%
May 13, 2022
Maintains: Outperform
Price Target: $60 → $59
Current: $7.36
Upside: +701.63%
May 11, 2022
Maintains: Outperform
Price Target: $18 → $17
Current: $0.89
Upside: +1,802.63%
Feb 25, 2022
Maintains: Outperform
Price Target: $16 → $9
Current: $1.48
Upside: +508.11%